Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Leonardi, C; Maari, C; Philipp, S; Goldblum, O; Zhang, L; Burkhardt, N; Ball, S; Mallbris, L; Gonzalez, P; Fernández-Peñas, P; Puig, L.
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
J Am Acad Dermatol. 2018; 79(5):824-830
Doi: 10.1016/j.jaad.2018.05.032
Web of Science
PubMed
FullText
FullText_MUG
- Authors Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis. To evaluate the efficacy and safety of IXE through 156 weeks from the UNCOVER-3 study in patients who were treated with the recommended dose regimen (160 mg of IXE at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter). Patients randomized to IXE every 2 weeks, IXE every 4 weeks, etanercept twice weekly, or placebo were switched to IXE every 4 weeks during the long-term extension period. Efficacy data were summarized by using the as-observed, multiple imputation, and modified nonresponder imputation methods. At week 156, 80.5% of patients had achieved at least a 75% improvement from baseline in their Psoriasis Area Severity Index (PASI) score, 66.0% had achived at least a 90% improvement from baseline in their PASI score, and 45.1% had achieved a 100% improvement from baseline in their PASI score with use of the modified nonresponder imputation method, and 97.2% and 86.2% of patients had achived at least a 75% improvement from baseline in their PASI score with use of the as-observed and multiple imputation methods, respectively. Similar response rates were observed in patients with baseline scalp, nail, or palmoplantar involvement. No new safety signals were identified through year 3. No placebo or active comparison after week 12. IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years. Copyright © 2018. Published by Elsevier Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Adult -
- Antibodies, Monoclonal, Humanized - administration & dosage
- Dose-Response Relationship, Drug -
- Double-Blind Method -
- Drug Administration Schedule -
- Esthetics -
- Etanercept - administration & dosage
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Markov Chains -
- Middle Aged -
- Psoriasis - diagnosis
- Psoriasis - drug therapy
- Severity of Illness Index -
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- efficacy
- interleukin 17
- ixekizumab
- long-term
- psoriasis
- safety
- UNCOVER-3